Your AI-Trained Oncology Knowledge Connection!
Cihangir Duy, PhD, MS, an assistant professor in the Nuclear Dynamics and Cancer research program and a member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, has been awarded an American Society of Hematology 2023 Junior Faculty Scholar Award in basic/translational research.
Researchers at Fox Chase Cancer Center were recently awarded a $550,000 grant from Stand Up To Cancer (SU2C) to fund a new project, “Accelerating and Diversifying Access to Clinical Trials.”
Fox Chase Cancer Center physicians Hossein Borghaei, DO, MS, and Elizabeth Plimack, MD, MS, have been named to the 2022 list of Highly Cited Researchers by Clarivate.
To synthesize advancements in the detection, treatment, and prevention of kidney cancer and summarize their effects globally, Fox Chase Cancer Center Urologic Oncology Fellow Laura Bukavina, MD, MPH, spearheaded a recent review on the topic.
The Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center are pleased to announce the hiring of Lucia Borriello, PhD, as an assistant professor in the Department of Cancer and Cellular Biology at Temple.
Fox Chase Cancer Center is pleased to announce the hiring of Lindsey B. Taylor, MD, as an assistant professor in the Department of Hematology/Oncology and the Breast Cancer and Hematology Programs.
Joining a list of over 100 previous orators, Robert Uzzo, MD, MBA, FACS, president and CEO of Fox Chase Cancer Center, delivered the Rhoads Oration for the Philadelphia Academy of Surgery this month at The College of Physicians of Philadelphia.
Billy Truong, a doctoral candidate at Fox Chase Cancer Center, was awarded the American Society of Hematology Abstract Achievement Award for a poster that he presented at the 64th ASH Annual Meeting and Exposition.
A study published by researchers at Fox Chase Cancer Center suggests that race itself may predict disparate outcomes between patients with head and neck cancer.
It’s long been known that DNA damage caused by environmental triggers, as well as other sources of oxidative stress, contribute to the development and progression of a wide variety of cancers.
Two Fox Chase Cancer Center researchers have received $75,000 grants from the Kidney Cancer Association to pursue studies that could improve kidney cancer treatment and care.
Robert Uzzo, MD, MBA, FACS, has been formally named president and chief executive officer of Fox Chase Cancer Center following a period of interim leadership.
Fox Chase Cancer Center is pleased to announce the hiring of Charnita Zeigler-Johnson, PhD, MPH, as Associate Director of Community Outreach and Engagement.
Jaye Gardiner, PhD, a postdoctoral fellow at Fox Chase Cancer Center, was recently awarded the Merton Bernfield Memorial Award from the American Society for Cell Biology, making her one of 18 scientists from across the country to be recognized for their achievements in the life sciences.
Fox Chase Cancer Center is pleased to announce the hiring of Anthony M. Villano, MD, as a clinical instructor in the Department of Surgical Oncology.
In a recent study, researchers at Fox Chase Cancer Center demonstrated how cancer cells can survive in the body even when faced with a lack of sufficient nutrition, a finding that could be used as a potential indicator of disease status in the organs of pancreatic cancer patients.
Researchers at Fox Chase Cancer Center have discovered that the drug efflux pump MDR1 promotes resistance to a promising new class of drugs called PROTACS—proteolysis-targeting chimeras.
Drs Bekaii-Saab, George, and von Mehren discuss patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating DCC-3116 in patients with RAS or RAF–mutated solid tumors, and how vimseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.
With two highly selective and active RET inhibitors approved for use in patients with metastatic RET alteration–positive non–small cell lung cancer, the dilemma is not determining which agent to select but ensuring that next-generation sequencing is done up front and in the presence of acquired resistance.
Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.
Multiple FDA-approved frontline immunotherapy options have continued to shape the treatment paradigm in non–small cell lung cancer. Additionally, more knowledge regarding the effects of immunotherapy on certain driver mutations has helped drive therapy decisions across lines of treatment.
The combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.
Elias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.
Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Deputy Director.
Jonathan D. Cheng, MD, discusses the various categories of immuno-oncology, including checkpoint inhibitors, immunotherapy combinations, and TKIs, that are moving the modality forward.
Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, was recently awarded a $50,000 grant from the Pennsylvania Breast Cancer Coalition.
Dr Jain discusses the current utility of frontline maintenance therapy in advanced ovarian cancer, dosing strategies with PARP inhibitors, and management strategies for common adverse effects associated with these therapies.
"If you stay at home too long, with too narrow a focus, you lose sight of what’s happening in the world."
Angela Jain, MD, provides perspective on use of PARP inhibitors in the treatment of patients with advanced ovarian cancer.
Margaret von Mehren, MD, discusses the value of ribociclib plus everolimus for patients with dedifferentiated liposarcoma, and how further research will be focused on biomarker analysis.
